Li Jinwei, Yan Xianlei, Liang Cong, Chen Hongmou, Liu Meimei, Wu Zhikang, Zheng Jiemin, Dang Junsun, La Xiaojin, Liu Quan
Department of Neurosurgery, The Fourth Affliated Hospital of Guangxi Medical University, Liuzhou, China.
College of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan, China.
Front Cell Dev Biol. 2022 Mar 10;10:840759. doi: 10.3389/fcell.2022.840759. eCollection 2022.
Gliomas are the most common and aggressive malignancies of the central nervous system. Histone deacetylases (HDACs) are important targets in cancer treatment. They regulate complex cellular mechanisms that influence tumor biology and immunogenicity. However, little is known about the function of HDACs in glioma. The Oncomine, Human Protein Atlas, Gene Expression Profiling Interactive Analysis, Broad Institute Cancer Cell Line Encyclopedia, Chinese Glioma Genome Atlas, OmicShare, cBioPortal, GeneMANIA, STRING, and TIMER databases were utilized to analyze the differential expression, prognostic value, and genetic alteration of HDAC and immune cell infiltration in patients with glioma. were considerable upregulated whereas HDAC11 was significantly downregulated in cancer tissues. were significantly correlated with the clinical glioma stage. were strongly upregulated in 11 glioma cell lines. High and low mRNA levels were significantly associated with overall survival and disease-free survival in glioma. are potential useful biomarkers for predicting the survival of patients with glioma. The functions of HDACs and 50 neighboring genes were primarily related to transcriptional dysregulation in cancers and the Notch, cGMP-PKG, and thyroid hormone signaling pathways. HDAC expression was significantly correlated with the infiltration of B cells, CD4 T cells, CD8 T cells, macrophages, neutrophils, and dendritic cells in glioma. Our study indicated that HDACs are putative precision therapy targets and prognostic biomarkers of survival in glioma patients.
神经胶质瘤是中枢神经系统最常见且侵袭性最强的恶性肿瘤。组蛋白去乙酰化酶（HDACs）是癌症治疗中的重要靶点。它们调节影响肿瘤生物学和免疫原性的复杂细胞机制。然而，关于HDACs在神经胶质瘤中的功能知之甚少。利用Oncomine、人类蛋白质图谱、基因表达谱交互式分析、布罗德研究所癌细胞系百科全书、中国神经胶质瘤基因组图谱、OmicShare、cBioPortal、GeneMANIA、STRING和TIMER数据库，分析HDACs的差异表达、预后价值以及神经胶质瘤患者的基因改变和免疫细胞浸润情况。在癌组织中，[具体基因未明确]显著上调，而HDAC11显著下调。[具体基因未明确]与临床神经胶质瘤分期显著相关。在11种神经胶质瘤细胞系中，[具体基因未明确]强烈上调。神经胶质瘤中[具体基因未明确]的高mRNA水平和低mRNA水平与总生存期和无病生存期显著相关。[具体基因未明确]是预测神经胶质瘤患者生存的潜在有用生物标志物。HDACs和50个相邻基因的功能主要与癌症中的转录失调以及Notch、cGMP-PKG和甲状腺激素信号通路有关。HDAC表达与神经胶质瘤中B细胞、CD4 T细胞、CD8 T细胞、巨噬细胞、中性粒细胞和树突状细胞的浸润显著相关。我们的研究表明，HDACs是神经胶质瘤患者生存的推定精准治疗靶点和预后生物标志物。
